Matrix metalloproteinase-9 is required for vasculogenic mimicry by clear cell renal carcinoma cells
- 1 April 2015
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 33 (4) , 168.e9-168.e16
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review)Oncology Letters, 2013
- Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinomaJournal of Surgical Oncology, 2013
- Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasisJournal of Experimental & Clinical Cancer Research, 2012
- Prognostic factors in renal cell carcinomaWorld Journal of Urology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cellsBiochemical and Biophysical Research Communications, 2009
- Combination targeted therapy in advanced renal cell carcinomaCancer, 2009
- Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma CellsJNCI: Journal of the National Cancer Institute, 2004
- Recurrence of renal cell carcinoma more than 5 years after nephrectomyInternational Journal of Urology, 2002
- Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic MimicryThe American Journal of Pathology, 1999